Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$42.95
+3.59%
Alpha Vantage · 11/10/2026
Adjusted daily closes · 252 observations · as of Nov 10, 2026
1 month
-10.9%
3 months
-13.8%
6 months
-8.8%
1 year
+12.8%
Year to date
+9.7%
52-week range
$37.04 – $53.07
Latest reported period: Sep 30, 2026
Market cap
$1.46B
P/E
7.8
P/B
2.1
P/S
0.1
Revenue
$23.45B
Net income
$215.7M
Diluted EPS
5.51
Gross margin
5.20%
Net margin
0.80%
Return on equity
26.50%
Total debt
$1.9B
Cash
$21.55M
Free cash flow
$346M
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $6.68B | $49.53M | 4.40% | 0.60% | $138.05M |
| Jun 30, 2026 | $6.79B | $70.99M | 4.80% | 0.90% | $275.02M |
| Mar 31, 2026 | $5.32B | $70.14M | 6.20% | 1.20% | -$131.38M |
| Dec 31, 2025 | $4.65B | $25.06M | 5.70% | 0.40% | $64.32M |
| Sep 30, 2025 | $4.69B | $29.03M | 5.80% | 0.50% | -$156K |
| Jun 30, 2025 | $4.63B | $25.21M | 5.90% | 0.40% | $201.62M |
| Mar 31, 2025 | $4.59B | $18.68M | 5.60% | 0.30% | -$65.87M |
| Dec 31, 2024 | $4.19B | $23.86M | 6.40% | 0.40% | -$192.08M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
PHOENIX (AZFamily) — The U.S. Food and Drug Administration now requires all weight loss drugs to carry a warning label about a potential increased risk of sudden blindness, according to new guidance from the...
Original sourceFDA warns GLP-1s could increase risk of vision loss Download Embed < iframe src="https://www.npr.org/player/embed/nx-s1-6035824/nx-s1-mx-6035824-1" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player"> Amanda Andrade-Rhoades/AP The Food and Drug Administration is warning that
Original sourceThe US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness.On...
Original sourceThe makers of GLP-1 medications like Ozempic and Wegovy must warn users about the risk of developing a condition that can cause blindness under the warnings and precautions section on labels, according to a...
Original sourceminutes agoMadeline HalpertGetty ImagesThe US Food and Drug Administration (FDA) told makers of popular weight-loss GLP-1 drugs that they must add warning labels about a rare eye condition that can cause...
Original sourceSupport WBURHere & Now NewsroomNovember 10, 2026The Food and Drug Administration has issued a new warning about a rare eye condition associated with GLP-1 medications, raising questions about the...
Original sourceWuXi removed from Trump’s chinese military list, the new Space Race, and more biotech news Adobe Elaine’s stories explore the boom in...
Original sourceA required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a...
Original source